XXXX and @entity782 maintenance after autologous transplant in @entity1582 .

@entity1 @entity137 @entity1295 @entity344 @entity1582 @entity1503 @entity6985 @entity782
UNASSIGNED: Single-agent post-autologous transplant maintenance therapy with @entity6985 is standard of care for @entity1 with @entity1582 . The tolerability and effectiveness of combination post-transplant maintenance therapy is unknown, so we investigated @entity6985 and @entity782 ( @entity782 ) in this setting, hypothesizing that the regimen would be well tolerated and associated with an improved post-transplant response. This trial followed a standard 3  *  3 dose escalation phase 1 design. @entity782 was administered beginning day +90 post-haematopoietic stem cell transplantation for days 1-7 and 15-21, and @entity6985 was started at 10  mg days 1-21, both on a 28-d cycle. The primary endpoint was maximum tolerated dose and dose limiting @entity137 were assessed during the first cycle. Treatment was well tolerated in 16 enrolled @entity1 . During Cycle 1, the most common @entity137 included @entity1503 , @entity344 and @entity1295 . Seven @entity1 improved their transplant response after starting combination therapy. The median follow-up was 38  4  months, and the median progression-free survival and overall survival have yet to be reached. This oral post-transplant maintenance regimen was well tolerated. This is the first trial to publish results on the use of a histone deacetylase inhibitor in the maintenance setting, and it provides rationale for the ongoing randomized trial in maintenance (ISRCTN 49407852). TRIAL REGISTRATION: NCT00729118.
